HELM: Healthy Aging Through Movement

Sponsor
University of Florida (Other)
Overall Status
Recruiting
CT.gov ID
NCT05772884
Collaborator
(none)
30
1
1
24.7
1.2

Study Details

Study Description

Brief Summary

This study aims to examine the effectiveness of a supervised aerobic exercise program for persons with Opioid Use Disorder (OUD). Participants will be enrolled in a 12-week supervised aerobic exercise intervention.

Condition or Disease Intervention/Treatment Phase
  • Other: Supervised Exercise Intervention
N/A

Detailed Description

The overall project goals are to test the feasibility and acceptability of our aerobic exercise intervention with this population. Study participation will include a screening and enrollment phase, a baseline assessment, and a 12-week intervention. Participants will be recruited and consented by University of Florida (UF) study staff.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
All participants receive the same (single) intervention.All participants receive the same (single) intervention.
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
The Potential of Exercise to Reduce Pain and Enhance Mobility in Mid-life Adults Undergoing Opioid Use Treatment
Actual Study Start Date :
May 11, 2022
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Supervised Exercise Intervention

Participants will be asked to complete 3 walking sessions per week for 12 weeks. We will ask them to complete at least 1 of these sessions in-person on-site and they will be given the option to complete up to 2 walking sessions per week off-site. Exercise training on-site will be performed on an indoor walking path, 50 min/session (plus 5 min. for each warm-up and cool down).

Other: Supervised Exercise Intervention
Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.

Outcome Measures

Primary Outcome Measures

  1. Recruitment feasibility [Baseline up to 4 weeks]

    Number of participants screened and enrolled with reasons for ineligibility and non-participation recruitment rate (participants enrolled/month

  2. Intervention adherence [Up to 13 weeks]

    Measured as percent study sessions completed on-time (+/- 1 hour of the scheduled session) and the proportion of participants who achieved >75% adherence.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults must be aged 21-64 years old

  • Currently enrolled in OMT (opioid maintenance treatment) or present with at least mild opioid use disorder (endorses at least 2 DSM-V criteria for OUD within a 12-month period),

  • Insufficiently physically active (defined as exercising < 20 minutes 3 times/week

  • Able to understand and speak English

  • Have a body mass index 18.5-40 kg/m^2

  • Willing and able to visit research center up to one time time/week for 12 weeks

  • Participants will undergo a supervised maximal exercise test and physical exam by medical supervisor to be cleared for participation.

Exclusion Criteria:
  • Participants must not have heart disease, or had a stroke, uncontrolled diabetes, thyroid condition an eating disorder

  • An uncontrolled major psychiatric condition (e.g., schizophrenia; conditions that are well-controlled, however [e.g., anxiety controlled through therapy] will not be exclusionary), or other medical condition(s) that contraindicate exercise; and may not be participating in a structured exercise training or weight loss program.

  • Participants cannot be pregnant; pregnancy is exclusionary

  • One individual per household may enroll.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Florida Gainesville Florida United States 32611

Sponsors and Collaborators

  • University of Florida

Investigators

  • Principal Investigator: Meredith S Berry, PhD, University of Florida

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Florida
ClinicalTrials.gov Identifier:
NCT05772884
Other Study ID Numbers:
  • IRB202002140
First Posted:
Mar 16, 2023
Last Update Posted:
Mar 17, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Florida
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 17, 2023